Emerging BioTalk
  • Home
  • About Us
  • Contact
  • Search
  • Menu

Planning for CEO Succession of Your Life Science Start-Up

March 30, 2022/in Uncategorized /by Barri Blauvelt

In life science start-ups, we know that one thing is likely (aside from death and taxes): At some point, you’ll want to move on to lead another start up. Handing over the reins of your current one, however, is never simple.

I read with great interest an exclusive interview of Hubert Joly, former CEO of Best Buy, in Chief Executive about “10 Keys to CEO Transition” https://chiefexecutive.net/is-your-company-ready-to-make-a-ceo-transition-here-are-the-10-keys-to-success/ , and that really got me thinking. Would the advice he shared in that interview work for life science start ups?  Yes…and no.

No, because much of the advice assumes there is a broad and deep organization from which to select and groom successors, or deep pockets to recruit a seasoned CEO to take over for you. That simply is not the case in a life science start-up.

However, I definitely agreed to some parts of the advice, but with caveats.

  1. Start with a long term succession plan.

While doing this roadmap virtually right from the start may seem premature – even crazy! – having been on boards of such companies I can assure you that in the back of most your early investors’ minds is the concern. “What if you got hit by a truck?”

Often in such small companies, the CEO is the brain and muscle behind the science and still intimately involved in leading the research.  You go, the company goes.

In big corporations, they either have CEO successors groomed or are prepared to recruit from a plethora of other big corporations. However, in the life science company filling your shoes may be nearly impossible unless you have selected people who can smoothly take over the reins to keep the R&D on track.  And to do that, they need to be intimate with what you are doing and how you do it.  So keeping each other informed is critical. This doesn’t mean a plethora of emails. It means more than working closely. It means taking extra time to discuss, share and ensure that what you know could be taken over and continued by them at any moment, with minimal disruption.  You can easily test their readiness by taking short vacations or breaks and letting them take over for you while gone, and not hitting the pause button, but do be available for consultation.  And when they do something differently than you would have, don’t jump down their throats. Understand what they did and why they did it that way. If not, it’s a learning opportunity for them (and you). You even may realize they do have better ways or ideas!

  1. Focus on executive development, not succession

I couldn’t agree more.

I hear from CEOs of life science companies, “If I groom them to potentially take over from me as CEO, and don’t make that happen, they’ll leave.”  Yes, you might lose them to another company, but if you don’t mentor and prepare them for future leadership roles, you are more likely to lose them faster than when you do show you value them now and want to build their value even more for the future.

But make sure you don’t imply or commit to a timeline. Be flexible, see how they develop. Your greatest success would be that they eventually are capable of taking over from you as you pursue other interests – whether in one year or five.

  1. Do formal assessments

My observation of most start-ups is that most lack good fundamental HR processes. “IDPs”, or Individual Development Plans, are a given in big corporations. But in small ones, they tend to be ignored.  The whole focus is in research development, not people development.  Bad idea.

A regular and structured performance review process allows for both parties to ensure that the requirements for success are clear. It also should foster an open and transparent discussion of managerial development needs. Think they don’t need that? Think again.

If you aren’t strengthening their future leadership skills along with keeping them on top of their field in science and medicine, you’ll never be able to replace yourself.  And while you are in that discussion, don’t forget to ask them for honest feedback on what you could be doing better, to be a better manager, mentor and leader of them.

  1. Implementing the Transition

Now, you are ready to move on to the next start up. The Board and you have agreed. Done? Not even close. This is perhaps the trickiest part.

If you haven’t already groomed a potential CEO replacement from within the company, you’ll need to recruit one from somewhere else. In fact, your Board might tell you who the new CEO should be.  When that CEO is announced, you risk some of your best – indeed, most critical – team members jumping ship.

The dilemma is that if you select someone over others in your small team, this may happen anyway.

To effectively manage this transition, use a consultative approach. (A great time to do this is during that IDP discussion.)  Ask them for their thoughts about future CEO succession planning. You might be surprised by their answers – not so much about considering them, but considering other team members or the type of person they would like to see take your place. Then, bring that person in, not as the CEO but in an important line leadership role that would make sense to the team. An experienced and approachable CFO or COO is the most likely type of candidate, but not the only choice.

The point is, that by the time your successor is announced, ideally the team should already have accepted, worked under and worked well with that person.

There is another, even more likely scenario, rather unique to life science start-ups.

If you as the CEO also are that brain and brawn of the science, the Board is likely to make you make a hard decision: Either be the CEO or be the Chief Scientific Officer.  Do you relish and are you truly qualified to handle the financial management and fund-raising aspects of the job? Are you good at dealing with investors and constant pressures of cash flow? Possibly – probably – not. So the Board could decide to replace you with a “numbers person”, likely one with the Street experience, great at schmoozing with investors.

What we do know is that at some point, you will have to make that hard choice or it will be made for you by the Board.  So think about your own transition – what skills do you need to develop for yourself to transition from bench research to business management?

The hardest thing to imagine is how to let the company you started be ‘given’ to a seasoned financially savvy CEO. Yet, it might just be the best thing you do.  So in planning for succession, consider your own transitioning – not necessarily to start a new life science company, but to be able hand the reins over to a CEO whom you will work side by side. After all, this gives the start up an even greater chance for success while letting you focus on what you feel most fulfilled and capable doing anyway: great research.

  • Author
  • Recent Posts
Barri Blauvelt
Chief Executive Officer at Innovara, Inc.
Barri Blauvelt
Chief Executive Officer at Innovara, Inc.
Barri Blauvelt, MBA, MPH, is CEO of Innovara, Inc., a leading global organizational development firm dedicated to talent development in life sciences and health care industries. In addition to leading Innovara, she holds adjunct faculty positions or serves as a guest lecturer and project director for leading schools of medicine and public health. She is well published in healthcare policy-informing research, particularly in cancer control strategies, and highly regarded as consultant, speaker and trainer in commercial strategy and medical affairs.

Steve Forbes: What's Ahead Podcast: Barri Blauvelt and the 'Two-Year-Old Question'

Barri Blauvelt on Linkedin
Latest posts by Barri Blauvelt (see all)
  • Planning for CEO Succession of Your Life Science Start-Up - March 30, 2022
  • Finding That Perfect Person for the Emerging Life Science Company - October 20, 2020
0
Share this entry
  • Share on Facebook
  • Share on Twitter
  • Share on LinkedIn
  • Share by Mail
http://emergingbiotalk.com/wp-content/uploads/2022/01/shutterstock_302958509_Skyscraper_01.26.22-scaled.jpg 1707 2560 Barri Blauvelt http://emergingbiotalk.com/wp-content/uploads/2020/05/emergingbiotalk-header.png Barri Blauvelt2022-03-30 11:21:492022-10-19 08:51:18Planning for CEO Succession of Your Life Science Start-Up

Biotech Resource Hub >>

  • SUBSCRIBE TO OUR BLOG
  • SUBMIT YOUR BLOG POST

Latest News

  • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
  • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
  • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

Categories

  • Bioprocessing
  • Biosafety Testing
  • End-to-End Solutions
  • Frontpage Article
  • Gene Therapy
  • Investigator's Brochure
  • News
  • Uncategorized
  • Vaccines
  • Viral Vectors
  • Webinar

Archives

  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • May 2020
  • April 2020
  • SUBSCRIBE TO OUR BLOG
  • SUBMIT YOUR BLOG POST

Latest News

  • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
  • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
  • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am

Categories

  • Bioprocessing
  • Biosafety Testing
  • End-to-End Solutions
  • Frontpage Article
  • Gene Therapy
  • Investigator's Brochure
  • News
  • Uncategorized
  • Vaccines
  • Viral Vectors
  • Webinar

Archives

  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • January 2021
  • December 2020
  • November 2020
  • October 2020
  • September 2020
  • August 2020
  • July 2020
  • May 2020
  • April 2020

Tags

applications bioprocessing biotech blazar Congratulations Content education Europe FDA Format gene therapy grant grants Investigator's Brochure molecule new NGS Pharmaceuticals program services symposia tags things Tone VAR2 viral assurance viral clearance virus virus detection winner

Business Hours

Our support Hotline is available 24 Hours a day: (555) 343 456 7891

  • Monday-Friday: 9am to 5pm
  • Saturday: 10am to 2pm
  • Sunday: Closed

Latest News

  • 5 Minutes could win you $275,000 in products and services!January 30, 2023 - 8:50 am
  • Upcoming Seminar in India: Fast track through regulatory challengesFebruary 6, 2023 - 1:10 pm
  • Enter for a chance to win $275,000 in products and services!January 9, 2023 - 11:14 am
  • The Future of BiopharmaDecember 6, 2022 - 4:39 am
  • Last chance: 3rd Annual Startup Symposium – Day 3November 10, 2022 - 5:39 am
  • The Lack of Funding for Women Entrepreneurs Doesn’t Stop Them from Launching – But We Still Have a Long Way to Go – And We Can Help Each Other. Assurea is ROOTING FOR YOU!October 21, 2022 - 8:27 am

Categories

  • Bioprocessing
  • Biosafety Testing
  • End-to-End Solutions
  • Frontpage Article
  • Gene Therapy
  • Investigator's Brochure
  • News
  • Uncategorized
  • Vaccines
  • Viral Vectors
  • Webinar
  • Author
  • Recent Posts
Barri Blauvelt
Chief Executive Officer at Innovara, Inc.
Barri Blauvelt
Chief Executive Officer at Innovara, Inc.
Barri Blauvelt, MBA, MPH, is CEO of Innovara, Inc., a leading global organizational development firm dedicated to talent development in life sciences and health care industries. In addition to leading Innovara, she holds adjunct faculty positions or serves as a guest lecturer and project director for leading schools of medicine and public health. She is well published in healthcare policy-informing research, particularly in cancer control strategies, and highly regarded as consultant, speaker and trainer in commercial strategy and medical affairs.

Steve Forbes: What's Ahead Podcast: Barri Blauvelt and the 'Two-Year-Old Question'

Barri Blauvelt on Linkedin
Latest posts by Barri Blauvelt (see all)
  • Planning for CEO Succession of Your Life Science Start-Up - March 30, 2022
  • Finding That Perfect Person for the Emerging Life Science Company - October 20, 2020
0
© 2020 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. | Privacy Policy | Cookie Settings
The 2021 EIT Health Catapult Winner An Introduction to the Biopharmaceutical Industry
Scroll to top

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. We use cookies in our website to give you the most relevant experience. By clicking or navigating the site, you are accepting the use of all our cookies according to our Cookie Policy / Privacy Statement. You are free to decide in the Cookie Settings which categories you would like to allow. Please note that depending on what you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy

Accept All CookiesCookie Settings

Cookie and Privacy Settings



Cookie Preferences

When you visit our website, we store cookies on your browser to collect information. The information collected might relate to you, your preferences or your device, and is mostly used to make the site work as you expect it to and to provide a more personalized web experience. However, you can choose not to allow certain types of cookies, which may impact your experience of the site and the services we are able to offer. Click on the different category headings to find out more and change our default settings according to your preference. You cannot opt-out of our First Party Strictly Necessary Cookies as they are deployed in order to ensure the proper functioning of our website (such as prompting the cookie banner and remembering your settings, to log into your account, to redirect you when you log out, etc.). For more information about how we use and share your data, please follow this link.
Privacy Statement

Necessary

Always Active
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.

Functional

These cookies enable the provision of advanced functionalities and are used for personalization. The cookies are set in particular in response to your actions and depend on your specific service requests (e.g., pop-up notification choices).Changes will take effect once you reload the page.

Targeting

These cookies may be set to learn more about your interests and show you relevant ads on other websites. These cookies work by uniquely identifying your browser and device. By integrating these cookies, we aim to learn more about your interests and your surfing behavior and to be able to place our advertising in a targeted manner.

Confirm My ChoicesAllow AllDisable All

loading

Please wait while you are redirected to the right page...

Please share your location to continue.

Check our help guide for more info.

share your location